2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2185

Direct Medical Costs for Medicare Patients with Rheumatoid Arthritis
Abstract Number: 229

Disability Status, Mortality, and Leading Causes of Death in Seropositive Rheumatoid Arthritis Patients: A Population-Based Study in Korea
Abstract Number: 2953

Disappearance of Autoantibodies in RA: Does It Occur with Current Treatment Strategies? a Long-Term Follow-up Study in Patients That Achieved DMARD-Free Sustained Remission
Abstract Number: 698

Discontinuation of Methotrexate or TNF Inhibitors in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Abstract Number: 1881

Discovery and Validation of Novel Disease Subsets in 806 Patients with Takayasu’s Arteritis across Four International Cohorts
Abstract Number: 37

Discovery of DWP213388, a Potent ITK and BTK Dual Target Inhibitor with Excellent Efficacy, As a Treatment for Autoimmune Diseases
Abstract Number: 2706

Discriminant Validity and Reliability of World Scleroderma Foundation (WSF) Definition of Skin Ulcers in Systemic Sclerosis
Abstract Number: 447

Discriminating between Central & Peripheral Pain Sensitization Using a Slowly Repeated Evoked Pain Protocol
Abstract Number: 2860

Disease Activity and Its Measurement in Patients with RA across the U.S.: Data from the Rheumatology Informatics System for Effectiveness (RISE) Registry
Abstract Number: 1840

Disease Activity in Rheumatoid Arthritis Patients Is Influenced By Countries’ Socioeconomics: Results from the Meteor Registry
Abstract Number: 2501

Disease Activity Is the Major Discriminator When Defining Refractory Rheumatoid Arthritis
Abstract Number: 614

Disease Activity One Year after Addition of Bucillamine or Sulfasaladine to Methotrexate in Japanese Patients with Rheumatoid Arthritis : Propensity Score Analysis
Abstract Number: 2633

Disease Activity, Organ Damage and Patient-Reported Outcome Measures in Swedish Patients with Recent-Onset SLE
Abstract Number: 1602

Disease Characteristics, Quality of Life, and Work Productivity By Enthesitis Sites: Real-World Data from the US Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Abstract Number: 1670

Disease Course Patterns in Systemic Lupus Erythematosus: Impact on Long-Term Outcomes

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].